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Abstract
Fibroblasts are important in orchestrating various functions necessary for maintaining normal tissue homeostasis as well as
promoting malignant tumor growth. Significant evidence indicates that fibroblasts are functionally heterogeneous with
respect to their ability to promote tumor growth, but markers that can be used to distinguish growth promoting from
growth suppressing fibroblasts remain ill-defined. Here we show that human breast fibroblasts are functionally
heterogeneous with respect to tumor-promoting activity regardless of whether they were isolated from normal or
cancerous breast tissues. Rather than significant differences in fibroblast marker expression, we show that fibroblasts
secreting abundant levels of prostaglandin (PGE2), when isolated from either reduction mammoplasty or carcinoma tissues,
were both capable of enhancing tumor growth in vivo and could increase the number of cancer stem-like cells. PGE2 further
enhanced the tumor promoting properties of fibroblasts by increasing secretion of IL-6, which was necessary, but not
sufficient, for expansion of breast cancer stem-like cells. These findings identify a population of fibroblasts which both
produce and respond to PGE2, and that are functionally distinct from other fibroblasts. Identifying markers of these cells
could allow for the targeted ablation of tumor-promoting and inflammatory fibroblasts in human breast cancers.
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Introduction
Fibroblasts were first described in the late 19
th century by the
pathologist Rudolph Virchow based on their residence within
connective tissues and their elongated, spindle-like shape [1]. As
the most prominent cell type within connective tissues, these
mesenchymal cells function to deposit and remodel extracellular
matrix (ECM), specify epithelial fate and maturation of tissues,
facilitate granulation of tissues post wounding and promote re-
epithelialization [2,3,4,5,6]. Fibroblasts are required for mammary
gland development, as signals from the underlying primary
mesenchyme are required to induce mammary placode elongation
and invasion to form the primitive mammary ductal tree [7].
In addition to regulating and maintaining tissue homeostasis,
fibroblasts are well established mediators of tissue fibrosis following
injury and promoters of epithelial tumor growth. During fibrosis,
the acquisition of epigenetic alterations [8] results in fibroblasts
with altered gene expression, conferring an increase in growth
factor production, ECM deposition, and proliferation [9]. During
carcinoma progression, the associated desmoplastic stroma
includes an abundance of alpha smooth muscle actin (aSMA+)
expressing fibroblasts, collectively referred to as cancer associated
fibroblasts (CAFs). These cells are also found in connective tissues
during wound healing and are frequently termed ‘‘myofibro-
blasts’’. These aSMA+ fibroblasts isolated from the stroma of solid
tumors can significantly promote the growth of breast [10,11,12],
prostate [13], pancreas [14], and skin cancer cells in mice [15].
Some of the tumor promoting mechanisms of these cells have been
established, such as increasing tumor angiogenesis and mediating
macrophage recruitment, both of which serve as a prominent
sources of growth factors and cytokines for the growth of tumor
cells [16]. Recently, aSMA+ myofibroblasts have also been shown
to possess a pro-inflammatory phenotype [15], suggesting that
these cells may contribute to the tumor associated inflammation
that accompanies the progression of tumors.
Despite the established functions of fibroblasts in tissue
homeostasis and disease, the molecular mechanisms contributing
to the phenotypic and functional heterogeneity among fibroblasts
remains largely unknown [17,18,19,20,21]. It has been reported
that the gene expression of fibroblasts derived from disease- free
breast tissue harbors a greater heterogeneity than those derived
from breast carcinomas, even within the same patient [22]. This is
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exists significant heterogeneity among the expression of aSMA
within the tumor associated stroma [23]. While aSMA is a
common marker routinely used to identify CAFs, these cells may
vary in the levels of aSMA expression [24], and it remains
unknown if robust expression of aSMA marks the most tumor
promoting fibroblasts within a given fibroblast population. It also
should be noted that several cell types in the tumor microenvi-
ronment, in addition to fibroblasts, will express aSMA [25,26,27],
and it is not a unique marker of CAFs or myofibroblasts.
Moreover, it is well established that fibroblasts isolated from
homeostatic tissues will acquire aSMA expression and stress fibers,
resembling the phenotype of myofibroblasts when explanted in
culture, exposed to TGFb, or exposed to tumor cell conditioned
media [28,29,30]. Because of this, maintaining the phenotypic and
functional discrepancy of fibroblasts from homeostatic versus
diseased tissues in culture has been extremely difficult.
Intriguingly, aSMA+ fibroblasts isolated from tumor associated
stroma are not the only source of fibroblasts that harbor the
capacity to support epithelial tumor growth. Fibroblasts isolated
from arthritic synovium can promote growth of co-mixed human
breast cancer cells in a xenograft mouse model of breast cancer
[31]. However, there are numerous examples to demonstrate the
tumor suppressive function of fibroblasts as well. For example, ras-
transformed mouse keratinocytes are unable to form tumors in
syngeneic animals when they are co-mixed with dermal fibroblasts
isolated from disease-free mouse skin [32]; initiated primary
human prostate epithelial cells do not form tumors under the renal
capsule when co-mixed with fibroblasts from disease free human
prostate tissues, unlike their CAF counterparts [13]. These
functional discrepancies among fibroblast populations remain to
be reconciled.
In this manuscript, we sought to understand the properties of
breast fibroblasts that contribute to a tumor promoting phenotype.
Using fibroblast populations isolated from both disease-free and
breast tumor tissues, we demonstrate for the first time that
the ability of fibroblasts to promote tumor growth is irrespective
of tissue source and correlates with the ability of these cells to
secrete PGE2 and respond to PGE2 signaling. These data may
lend insight into the dichotomy among the tumor promoting or
tumor suppressive functions of various fibroblast populations,
and warrants the investigation of novel markers for these cells
among heterogeneous fibroblast populations. Discovery of such
markers may elucidate which patients in the clinic would largely
benefit from an adjuvant therapy targeting both the eradication of
tumor cells and the tumor promoting fibroblasts within the tumor
stroma.
Materials and Methods
Isolation of primary fibroblasts from human breast
tumors and reduction mammoplasty tissues
All human breast tissue procurement for these experiments was
obtained in compliance with the laws and institutional guidelines,
as approved by the institutional IRB committee from Tufts
University School of Medicine. Primary breast tumor tissues were
obtained from discarded material at Tufts Medical Center and
non-cancerous breast tissue was obtained from patients undergo-
ing elective reduction mammoplasty at Tufts Medical Center.
Breast tissues were minced and enzymatically digested overnight
with a mixture of collagenase and hyaluronidase as previously
described [33,34]. Large clusters of undigested tissue were allowed
to settle and the supernatant enriched for stromal cells was
collected, washed and plated in serum containing medium to
enrich for mammary fibroblasts. Cells were grown in DMEM
supplemented with 10% calf serum (CS) and antibiotic/antimy-
cotic (AB/AM, Invitrogen, Carlsbad, CA) for multiple passages
until senescent as described previously [34]. Senescent fibroblasts
were not included in subsequent experiments.
Cell cultures, conditioned media collection, and cell
treatments
Fibroblasts were grown as described above. MCF7 breast
cancer cells were grown in DMEM+10% CS+1% AB/AM. All
cultures were maintained at 37 uC and 5% CO2. To generate
conditioned media, fibroblasts were seeded at 1.5610
6 cells/plate
in phenol red free DMEM (PRF-DMEM, Invitrogen), supple-
mented with either 0.5% or 2% charcoal/dextran stripped FBS
(Invitrogen) and 1% AB/AM, treated with ethanol or 0.5 mM
PGE2 (Sigma-Aldrich, St. Louis, MO), or left untreated, for
72 hrs. CM was then harvested, filtered through a 0.22 mm filter
(Millipore, Danvers, MA), aliquoted and stored at 280uC. For
MCF7 treatments, cells were grown in PRF-DMEM supplement-
ed with 5% charcoal/dextran stripped FBS, 1% AB/AM, and
treated with ethanol, 0.5 mM PGE2, or 1 nM 17-b-Estradiol
(Sigma Aldrich). For MCF7 treatments involving fibroblast CM,
CM was collected as previously described, supplemented with 5%
charcoal/dextran stripped FBS, and administered to MCF7 cells
for 6 days. a-IL6 and recombinant human IL-6 (R&D Systems,
Minneapolis, MN) were used at 1.5 mg/mL and 10 ng/mL,
respectively.
Preparation of cells for mouse mammary fat pad
inoculation
All animal procedures were performed in accordance with an
approved protocol by Tufts University Institutional Animal Care
and Use Committee. A colony of NOD/SCID mice was
maintained under sterile housing conditions and received food
and water ad libum. Nulliparous female mice between 8 to 14 weeks
age were utilized in all experiments. For co-mixing experiments,
1.5610
6 human breast fibroblasts were mixed with 500,000
MCF7 breast cancer cells, resuspended in a 3:1 (vol/vol) ratio of
media to Matrigel (BD Biosciences, San Jose, CA) mixture, and
inoculated into the 4
th inguinal mammary gland. Tumor
formation was assessed by palpitation weekly. For MCF7 limiting
dilution experiments, 500,000 MCF7 cells were cultured in
conditioned media (CM) from PGE2-treated fibroblasts for 6
days, after which 10,000 cells were resuspended in a 3:1 (vol/vol)
ratio of media to Matrigel mixture, and inoculated into the 4
th
inguinal mammary gland. Tumor formation was assessed by
palpitation weekly.
Immunofluorescence
Fibroblasts were seeded at 5,000 cells/well of 8 well-chamber
slides (Becton Dickinson, Franklin Lakes, NJ) in DMEM+10%
CS+1% AB/AM (Invitrogen) for 96 hours before fixed in
methanol. Cells were then permeabilized with 0.1% Triton X-
100 (Sigma) in PBS, washed and blocked in 1% BSA in PBS at
ambient temperature. Cells were incubated with the following
antibodies overnight at 4 uC: mouse a-alpha SMA (1:200, Vector
Labs, Burlingame, CA), mouse a-Vimentin (1:200, Vector Labs),
mouse a-prolyl-4-hydroxylase (1:300, Millipore), and mouse a-
caveolin-1 (1:150, Novus Biologicals, Littleton, CO). Fluorescence
signal was detected using goat a-mouse secondary antibodies
(1:500, conjugated with Alexa488 and Alexa588, Invitrogen).
Nuclei were stained with 49, 6-diamidino-2-phenylindole (DAPI)
and images were captured with the Spot imaging software system
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tion was performed using Image-J software.
Quantitative Real Time PCR
RNA was isolated and purified using an RNeasy kit (Qiagen,
Valencia, CA) for cultured cells. RNA was reverse transcribed to
cDNA using an iScript cDNA synthesis kit (Biorad). Quantitative
real time PCR analysis was performed using SyBR Green and an
iCycler thermocycler (Biorad). Primer sequences used for quan-
titative real-time PCR are listed in Table S1.
Flow cytometry
Nonconfluent cultures of MCF7 cells were trypsinized into
single cell suspension, counted, and resuspended in FACS buffer
(PBS+3% CS). 100,000 cells were stained with the following
antibodies for 15 minutes at ambient temperature: a-human
CD24-PE (BD Biosciences), a-human CD44-APC (BD Bioscienc-
es), a-human ESA-FITC (Stem Cell Technologies, Vancouver,
BC, Canada), and isotype controls for each antibody (Mouse
IgG2a-PE, Mouse IgG2b-APC, Mouse IgG1-FITC, BD Bioscienc-
es). Unbound antibody was washed away with FACS buffer, and
cells were analyzed no longer than 1 hr post staining on a BD
FACS Calibur.
Tumorsphere assays
Fibroblasts were treated with either ethanol or 0.5 mM PGE2,
and conditioned media was prepared as described above. Upon
use, conditioned media was supplemented with 5% charcoal/
dextran-stripped FBS. MCF7s were dissociated to a single cell
suspension, plated at 20,000 cells/ml, and grown on ultra-low
adherence 6-well plates (Corning Life Sciences, Lowell, MA) in the
presence of supplemented conditioned media for 6 days. For
recombinant human IL-6 studies or exogenous PGE2 studies,
MCF7s were plated as described above in the presence of PRF-
DMEM supplemented with 5% charcoal/dextran-stripped FBS
and the following treatments: 0.1% BSA in PBS or 10 ng/mL
recombinant human IL-6 (R&D Systems), or ethanol or 0.5 mM
PGE2 (Sigma Aldrich). Tumorspheres were quantified using a
Multisizer-3 coulter counter (Beckman-Coulter, Brea, CA).
PGE2 enzyme immunoassay
Fibroblast conditioned media was prepared as described above
and subjected to a Prostaglandin E2 monoclonal EIA kit according
to the manufacturer’s instructions (Cayman Chemical, Ann Arbor,
MI). Concentration (pg/ml) was determined by generating a
standard curve with known concentrations of PGE2. Absorbance
was read at 405 nm using a 96 well plate mQuant spectropho-
tometer (Biotek, Winooski, VT) and the KC Junior software
program (Biotek).
Cytokine array
Fibroblasts were treated with either ethanol or 0.5 mM PGE2,
and CM was prepared as described above. Human cytokine arrays
(2000 series, RayBiotech, Norcross, GA) were exposed to CM
isolated from ethanol or 0.5 mM PGE2-treated fibroblasts and
processed according to the manufacturer’s instructions. Exposed
films were quantified for chemiluminescence intensity using a
Xenogen phosphoimager.
IL-6 ELISA
Fibroblast conditioned media was prepared as described above
and subjected to a human specific IL-6 ELISA according to the
manufacturer’s instructions (eBiosciences, San Diego, CA).
Concentration (pg/ml) was determined by generating a standard
curve with known concentrations of recombinant human IL-6.
Absorbance was read at 450 nm using a 96 well plate mQuant
spectrophotometer (Biotek, Winooski, VT) and the KC Junior
software program (Biotek). Concentrations were normalized to
total numbers of fibroblasts after 72 hour exposure to either
ethanol or 0.5 mM PGE2 and reported as arbitrary units.
Western blotting
MCF7 cells were seeded at 250,000 cells/well and exposed to
CM or treatments as described above. After 6 days, cells were
pelleted and lysed in RIPA buffer to prepare cell lysates. Fibroblast
conditioned media was prepared as previously described and
concentrated using.
Amicon Ultra Centrifugal Filters (Millipore). Protein concen-
tration from both lysates and conditioned media was determined
using a Lowry Assay according to manufacturer’s instructions
(Biorad, Hercules, CA). 30 or 50 mg of protein was resolved on a
4–12% polyacrylamide gel, transferred to a nitrocellulose
membrane (Biorad), and immunoblotted using the following
antibodies: mouse a-GAPDH (1:5000, Millipore), mouse a-
phosphorylated-STAT3 (Y705, 1:1000, Cell Signaling Technolo-
gies, Danvers, MA), rabbit a-total-STAT3 (1:2000, Cell Signaling
Technologies), mouse a-Cox-2 (Cayman Chemical), mouse a-
Cox-1 (Cayman Chemical), or rabbit a-IL6 (1:10,000, Abcam,
Cambridge, MA). Signal was detected using HRP-conjugated goat
a-mouse (1:14,000) or goat a-rabbit (1:12,000) secondary anti-
bodies (Cell Signaling) and West Dura Extended Chemilumines-
cence Substrate (Fisher).
Immunohistochemistry
Tumor tissues from MCF7 xenografts were fixed in 10% neutral
buffered formalin and paraffin embedded with standard proce-
dures. Tumor sections were deparaffinized, re-hydrated through
graded ethanols and subjected to heat-induced antigen retrieval.
Staining was performed by the Department of Pathology Core
Facility at Tufts Medical Center.
Results
Isolation and characterization of fibroblasts from human
breast tissues
We obtained fibroblasts from a variety of resected breast tissue
samples (Table 1): those derived from breast tumor specimens of
varying hormone receptor and HER2 status, and those derived
from disease-free reduction mammoplasty tissues. Given the
inability to prospectively sort for different populations of
fibroblasts due to the lack of established and unique cell surface
markers for these cells, we used the ability of fibroblasts to
preferentially adhere to plastic and grow ex-vivo under defined
conditions. Quantitative RT-PCR and immunofluorescence were
used to characterize and verify that the cells isolated from human
breast tissues were indeed enriched in fibroblasts.
We first assayed for the expression of fibroblast and epithelial
markers to ascertain the purity of the cultured stromal cells. Cells
were largely negative for cytokeratin 18 (CK18) and cytokeratin 14
(CK14) expression (Fig. 1A, Fig. S1B), indicating these cells were
devoid of breast epithelial cells. All patient derived fibroblasts
robustly expressed vimentin and prolyl-4-hydroxylase (P4H)
(Fig. 1B and Fig. S1A). In addition to these fibroblast markers,
we also assayed for the expression of aSMA, a marker of
myofibroblasts and cancer associated fibroblasts (CAFs). Consis-
tent with previous reports, aSMA expression in vivo was only
present within the stroma associated with breast tumors but not
Heterogeneity of Human Breast Fibroblasts
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However, cultured fibroblasts isolated from all the different patient
samples acquired aSMA expression as previously reported
[29,35,36]; expression was similar among patient derived
fibroblasts despite differences in expression in vivo. Interestingly,
none of the patient derived fibroblasts, regardless of the tissue
source of origin, were more than 50% aSMA positive as measured
by immunofluorescence (Fig. 1B); there was no significant
difference in aSMA expression among these patient samples
(Fig. 1B, p=0.1433). We corroborated these immunofluorescence
results by quantitative RT-PCR (Fig. 1D). Moreover, to avoid the
confounding effects of serum-induced aSMA expression in
cultured cells, we serum starved patient derived fibroblasts for
96 hours. Even under serum starvation conditions for this
extended period of time, the levels in aSMA expression between
these patient samples did not change (data not shown).
Recently, fibroblast surface protein (FSP) and fibroblast
activation protein (FAP) have been reported to distinguish
different types of fibroblasts in tumor tissues. Therefore, we also
examined FSP and FAP expression in breast tissue derived
fibroblasts. Both CAFs and disease-free breast fibroblasts harvest-
ed from several different patient samples expressed high transcript
levels of these two proteins (Fig. 1D).
Given that aSMA, FSP or FAP expression in vitro could not
distinguish fibroblasts isolated from human breast tumor speci-
mens versus fibroblasts isolated from disease-free human breast
tissues, we sought to identify other proteins whose expression may
be enriched in one tissue source or the other. Recently, expression
of Caveolin-1 has been reported to be downregulated in CAFs
compared to disease-free fibroblasts, and loss of Caveolin-1 in
mammary stromal fibroblasts promotes a tumor promoting, CAF-
like phenotype [37,38,39]. However, we found high expression of
Caveolin-1 in fibroblasts from both breast tumor specimens and
disease-free tissues, indicating that, similar to aSMA, this protein
could not distinguish between these cell types in vitro (Fig. S1A).
An inflammatory phenotype correlates with fibroblast
tumor promoting ability
Given the lack of specific marker expression between fibroblasts
isolated from breast tumor tissues versus fibroblasts isolated from
disease-free breast tissues, we sought to assay for functional
differences in promoting mammary tumor growth in vivo.
Accordingly, we co-mixed fibroblasts from 5 different tissue
sources (patients A, C, E, I and K) with weakly tumorigenic,
estrogen-dependent MCF7 cells, and inoculated ad-mixed cells
into the inguinal mammary fat pad of female NOD/SCID mice.
Fibroblasts derived from tissue samples C, K, and E co-mixed with
MCF7 cells formed larger tumors than MCF7 cells injected alone,
whereas fibroblasts derived from tissue sample I failed to support
MCF7 tumor growth (p=0.02, Fig. 2A), and only supported
tumor formation 50% of the time (Fig. 2B). Thus, tumor
promoting ability of fibroblasts did not depend on their tissue
source of origin (i.e. breast tumor or reduction mammoplasty,
Table 1), nor did it associate with their extent of aSMA, FSP, FAP,
or Caveolin-1 expression (Fig. 1 and Fig. S1A).
Based on these findings, we sought to identify characteristics of
these tissue derived fibroblasts that could resolve the differences in
their ability to support MCF7 tumor growth. Recent reports have
indicated that CAFs express an NFkB mediated pro-inflammatory
secretome that is required for their ability to support tumor growth
[15]. Thus, we hypothesized that fibroblasts differ in their inherent
pro-inflammatory state, which might account for their tumor
promoting capabilities in vivo. In fact, all tissue-derived fibroblasts
in vitro, regardless of their tissue of origin, expressed cyclooxygen-
ase-2 (Cox-2), an enzyme upregulated during tissue inflammation
and tumorigenesis [40], as well as its isoform Cox-1 (Fig. 2C and
Fig. S2). Both Cox-2 and Cox-1 catalyze the synthesis of the pro-
inflammatory hormone prostaglandin E2 (PGE2), although Cox-1
is thought to be constitutively expressed in most tissues and likely
responsible for producing the levels of prostaglandins required for
normal tissue function [41].
Given that these tissue-derived fibroblasts express Cox-1 and
Cox-2, we assayed for the levels of PGE2 in the conditioned media
(CM) from these cells. Fibroblasts from 8 different tissue samples
were serum starved for 72 hrs in phenol-red free DMEM, upon
which the CM was collected, filtered, and assayed for the concen-
tration of the pro-inflammatory hormone PGE2 by a specific
immunoassay. CM from several different tissue samples exhibited
significant differences in PGE2 secretion (p=2.84610
212): low
(,50 pg/ml; patient sample I), medium (50–150 pg/ml; tissue
Table 1. Summary of tissue derived fibroblasts used for this study.
Patient ID Tissue Source aSMA Expression Basal IL-6 Secretion PGE2 Secretion
A Mastectomy; ER+/HER22/BRCA1 carrier Medium Low Medium
C Mastectomy; ER2/HER22 Low Low High
D Invasive lobular carcinoma; ND ND Low ND
E Invasive ductal carcinoma; ER2/PR2/HER2+ Medium Medium Medium
F Lumpectomy; ND ND ND Medium
G Mastectomy; ER+/HER22 ND ND ND
H Phyllodes tumor ND ND ND
I Mammoplasty; disease free High Low Low
J Mammoplasty; disease free ND Medium Medium
K Mammoplasty; disease free Low Low High
L Mammoplasty; disease free ND Medium ND
M Mammoplasty; disease free Low Medium Medium
N Mammoplasty; disease free Medium ND ND
aSMA expression is defined as: low, ,45% positive; medium, 45–55% positive; high, .55% positive. ND, not determined.
doi:10.1371/journal.pone.0024605.t001
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24605Figure 1. Characterization of patient derived fibroblasts from human breast tumor tissues and reduction mammoplasty tissues. (A)
Quantitative RT-PCR for the relative levels of breast epithelial markers CK18 and CK14 transcripts in tissue derived fibroblasts from patient samples A,
C, M and N. MCF7 and immortalized human mammary epithelial cells (HME) serve as positive controls for CK18 and CK14, respectively. (B), Top,
immunofluorescence for the expression of mesenchymal markers vimentin and prolyl-4-hydroxylase (P4H) in tissue-derived fibroblasts from patient
samples A, C, M and N. Nuclei are stained with DAPI. Scale bar, 50 mm. Bottom, quantification of the percentage of aSMA+ cells per total number of
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(Fig. 2D). Intriguingly, we found a correlation between the ability
to secrete high levels of PGE2 in vitro and the ability to promote
MCF7 tumor growth in vivo. In fact, there was a statistically
significant difference in the ability to support MCF7 tumor growth
between high PGE2 secreting fibroblasts (K) compared to low
PGE2 secreting fibroblasts (I) (p=0.004). These findings suggest
that unlike aSMA, FAP, FSP, or Caveolin-1 expression, the ability
to secrete PGE2 may contribute to the tumor promoting
phenotype of fibroblasts.
Secreted factors from tumor-promoting fibroblasts
expand breast cancer stem-like cells
It is known that breast tumors are comprised of cells with
varying tumorigenic potential. Using primary human breast
cancer tissues, it has been demonstrated that the CD44
+/
CD24
2/EpCAM
+ population of cells can support tumor initiation
with as few as 100 cells and have self-renewing, stem-like
properties [42]. These ‘‘aggressive’’ cell populations are retained
within commonly used breast cancer cell lines, with MCF7 cells
having a basal percentage of 0.03% [33,43]. Because high PGE2-
secreting fibroblasts support MCF7 tumor growth, we hypothe-
sized that these fibroblasts may secrete factors that expand the
most aggressive, tumorigenic cells within the tumor bulk. To
determine if fibroblasts could expand this aggressive cell
population, we treated MCF7 cells for 6 days with CM isolated
from serum starved tissue-derived fibroblasts exhibiting varying
degrees of PGE2 secretion in vitro. We quantified the percentage of
aggressive, CD44
+/CD24
2/EpCAM
+ stem-like cells by FACS
following this 6-day treatment. CM from fibroblasts of varying
tumor promoting potential and PGE2 secretion had significant
differences in their ability to expand the percentage of aggressive
MCF7 cells (Fig. 3A, p=0.0007). Interestingly, those fibroblasts
exhibiting high levels of PGE2 secretion resulted in a significant
increase in the proportion of aggressive MCF7 cells compared to
those fibroblasts that had medium or low secretion of PGE2 in vitro
(E vs K, p=0.007; F vs K, p=0.005; J vs K, p=0.01). Moreover,
the ability to expand CD44
+/CD24
2/EpCAM
+ cells was
associated with the ability to support MCF7 tumor growth in vivo
(Fig. 3A and Fig. 2A, respectively).
Recently, it has been reported that PGE2 is necessary for the
expansion of bone marrow hematopoietic stem cells [44]. Since
fibroblasts exhibiting high levels of PGE2 secretion also exhibited
the most robust increase in cancer stem-like cells and promoted
the largest MCF7 tumor formation, we reasoned that paracrine
production of PGE2 by fibroblasts might be sufficient to expand
CD44
+/CD24
2/EpCAM
+ MCF7 stem-like cells. Therefore, we
treated MCF7 cells with 0.5 mM PGE2, 1 nM 17-b-estradiol (E2,
positive control), or EtOH (vehicle) for 6 days, and quantified the
percentage of CD44
+/CD24
2/EpCAM
+ cells by FACS. We
found, however, that PGE2 alone was not sufficient to expand
aggressive MCF7 cells (Fig. 3B).
Given the striking association between the ability of fibroblasts
to secrete PGE2 in vitro and the ability to expand CD44
+/CD24
2/
EpCAM
+ cells and support tumor growth, we speculated that
perhaps PGE2 signaling enhances the tumor promoting pheno-
types of fibroblasts. To test this hypothesis, we chose to examine
the CM from fibroblast patient samples who did not robustly
enhance the growth of MCF7 breast cancer cells in vivo (patient
samples A and I, Fig. 2A). First, we confirmed that these tissue-
derived fibroblasts express prostanoid receptors EP1, EP2, EP3
and EP4, making them sensitive to PGE2 signaling (Fig. S2B).
Next, we exposed these tissue-derived fibroblasts to exogenous
0.5 mM PGE2 or EtOH (vehicle) for 72 hours before harvesting
CM. We then exposed MCF7 cells to this CM for 6 days before
quantifying the population of CD44
+/CD24
2/EpCAM
+ cells by
FACS. Interestingly, exposure to PGE2 before CM collection
significantly augmented the ability of tissue sample A to increase
the percentage of CD44
+/CD24
2/EpCAM
+ cells (Fig. S3),
suggesting that PGE2 enhanced fibroblast tumor promoting
ability. However, exposure to PGE2 did not significantly enhance
the ability of tissue sample I to increase expansion of CD44
+/
CD24
2/EpCAM
+ cells (Fig. S3), despite prostanoid receptor
expression (Fig. S2B).
We also performed in vitro and in vivo functional assays of MCF7
tumorgenicity using CM from PGE2- or vehicle (EtOH) treated
fibroblasts. Specifically, MCF7 cells were grown under non-
adherent culture conditions to promote tumorsphere formation in
the presence of CM from PGE2- or vehicle (EtOH) treated
fibroblasts of varying tumor promoting capability and endogenous
PGE2 secretion status. As expected, CM from PGE2 treated tissue
derived fibroblasts (tissue samples A, C and K), formed
significantly more tumorspheres than those treated with CM from
vehicle treated fibroblasts (A, p=0.014; C, p=0.001; K,
p=0.0006; Fig. 3C). However, CM from fibroblasts derived from
tissue sample I did not significantly enhance MCF7 tumorsphere
formation when primed with exogenous PGE2 (Fig. 3C), consis-
tent with the inability to further enhance CD44
+/CD24
2/
EpCAM
+ cell expansion (Fig. S3B). Importantly, 0.5 mM PGE2
was not sufficient to enhance MCF7 tumorsphere formation
compared to vehicle control (Fig. 3C).
We also sought to demonstrate that fibroblasts primed with
PGE2 promote the aggressiveness of MCF7 cells in vivo. To this
end, we exposed MCF7 cells first in vitro to CM from PGE2-treated
tissue sample A, or CM from PGE2-treated tissue sample I, for 6
days to enrich for aggressive CD44
+/CD24
2/EpCAM
+ cells.
After 6 days, 10
4 cells from each cohort were inoculated into the
inguinal mammary gland of NOD/SCID mice. MCF7 cells
exposed in vitro to CM from PGE2-treated tissue sample A formed
significantly larger tumors than those exposed in vitro to CM from
PGE2-treated tissue sample I (p=0.03, Fig. 3D). Histological and
immunohistochemical analysis of these tumors revealed that the
tumors were all ERa- and E-cadherin-positive with a significant
degree of central necrosis, (Fig. 3E). Interestingly, tumors derived
from MCF7 cells exposed in vitro to CM from PGE2-treated tissue
sample A exhibited reduced p53 and CK8/18 expression
compared to those tumors formed from MCF7 cells exposed to
CM from PGE2-treated tissue sample I (Fig. 3E, p=0.02).
Together, these data suggest that PGE2 signaling in fibroblasts
enhances their tumor promoting abilities, resulting in expansion of
aggressive tumor cell populations and increased tumor growth.
PGE2 mediated IL-6 secretion by tumor-promoting
fibroblasts
Since PGE2 alone was not sufficient to confer expansion of
aggressive cancer stem-like cells (Fig. 3A), we hypothesized factors
cells in a given field. (C), H&E stains and aSMA immunohistochemistry of human breast tumor tissue sections (A, C) and human reduction
mammoplasty tissue sections (M, N) from which fibroblasts were derived. Scale bar, 50 mm. (D) Quantitative RT-PCR for the relative levels of aSMA,
FAP, and FSP transcripts in tissue-derived fibroblasts from patient samples A, C, M and N after propagating in vitro. HL60 cells are shown as a negative
control. Statistics were performed with a single factor ANOVA, p=0.143).
doi:10.1371/journal.pone.0024605.g001
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PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24605produced from PGE2-stimulated fibroblasts were essential for this
expansion. To identify the secreted proteins mediating breast
cancer stem-like expansion, we examined the CM from PGE2-
treated or vehicle-treated tissue derived fibroblasts from patient A,
and quantitatively assayed for 164 secreted growth factors and
cytokines using an antibody-based protein array. We observed that
the secretion of IL-6 was increased at least 5 fold upon PGE2-
treatment compared to vehicle-treated control (Fig. S4A).
To more comprehensively assess whether PGE2 treated
fibroblasts secrete IL-6, we performed both qualitative and
quantitative assays. We first isolated CM from PGE2 or vehicle
treated fibroblasts from 3 patient derived tissue samples (C, A, and
G), concentrated the CM, and immunoblotted for IL-6 (Fig. 4A).
Nearly all patient samples showed an increase in IL-6 secretion
upon exposure to PGE2, supporting the cytokine array results. For
a more quantitative assessment of IL-6 secretion, we performed a
human specific IL-6 ELISA with CM prepared from various
breast tissue derived fibroblasts treated with either 0.5 mM PGE2
or EtOH (vehicle) for 3 days. Although the fold induction of IL-6
secretion in response to PGE2 was heterogeneous among tissue
derived fibroblasts, nearly all patient samples showed at least a 1.5
fold increase in IL-6 secretion upon treatment with PGE2 (Fig. 4B).
However, the induced secretion of IL-6 by PGE2 (Fig. 4B), as well
as the basal levels of IL-6 secretion in these tissue derived
fibroblasts (Fig. S4B) both failed to associate with the tumor
promoting abilities of these fibroblasts in vivo (Fig. 2A), or their
ability to secrete PGE2 in vitro (Fig. 2C). Collectively, these data
suggest that unlike high PGE2 secretion, high basal IL-6 secretion
or PGE2 mediated induction of IL-6 secretion, are not necessarily
hallmarks of tumor promoting fibroblasts.
IL-6 is necessary but not sufficient for tumor-promoting
fibroblasts to expand stem-like cells
It has been reported that IL-6 enhances aggressive, stem-like
features in sphere-forming populations of human mammary
epithelial cells [45], and mediates a positive feedback loop that
maintains oncogenic transformation [46]. Thus, we suspected it
might be an essential cytokine produced by fibroblasts that is
required for expansion of CD44
+/CD24
2/EpCAM
+ cells. To test
this, we exposed MCF7 cells to CM from PGE2- or vehicle
(EtOH) treated fibroblasts from tissue sample A and tissue sample
I for 6 days in the presence of an IL-6 neutralizing antibody (aIL-
6) or goat IgG control. Quantifying the percentage of CD44
+/
CD24
2/EpCAM
+ cells by FACS revealed that PGE2 significantly
enhanced the ability of fibroblasts from tissue sample A to support
expansion of CD44
+/CD24
2/EpCAM
+ cells (p=0.003, Fig. 4C)
in an IL-6 dependent manner, as the expansion was attenuated in
the presence of an IL-6 neutralizing antibody (aIL-6, p=0.0004).
PGE2 did not enhance the ability of fibroblasts from tissue sample
I to support CD44
+/CD24
2/EpCAM
+ cell expansion, despite
some IL-6 present in the CM (Fig. 4C).
Given that IL-6 is necessary for fibroblast mediated expansion
of CD44
+/CD24
2/EpCAM
+ cells, we asked if IL-6 was sufficient
to confer this expansion. We treated MCF7 cells with 10 ng/mL
recombinant human IL-6 or 0.1% BSA (vehicle), in either the
presence or absence of 0.5 mM PGE2 or EtOH (vehicle).
Interestingly, IL-6 alone, or in combination with 0.5 mM PGE2,
was not sufficient to expand CD44
+/CD24
2/EpCAM
+ MCF7
cells, unlike 1 nM E2 (Fig. 4D). Also, IL-6 alone was not sufficient
to confer increases in MCF7 tumorsphere formation (Fig. 4E). To
confirm that MCF7 cells were capable of signaling through IL-6,
we exposed MCF7 cells for 30 min to CM from PGE2 or EtOH
treated fibroblasts of differing tumor-promoting capabilities, in the
presence of an IL-6 neutralizing antibody or goat IgG control, and
immunoblotted for the levels of phosphorylated STAT3 as an
indicator of the IL-6 signaling pathway. pSTAT3 levels were
higher in MCF7 cells exposed to CM from PGE2-treated
fibroblasts from patient sample A as compared to CM from
PGE2-treated fibroblasts from tissue sample I, and this was
abrogated by addition of aIL-6. Moreover, 0.5 mM PGE2 was not
sufficient to induce pSTAT3 expression, unlike the addition of
10 ng/mL recombinant human IL-6 (Fig. 4F). Collectively, these
data indicate that IL-6 is enriched in CM from several patient
tissue-derived fibroblasts, secreted by fibroblasts in response to
PGE2, and is necessary, but not sufficient, for fibroblast-mediated
expansion of CD44
+/CD24
2/EpCAM
+ MCF7 cells.
Discussion
Several studies have implicated fibroblasts as potent tumor
promoting stromal cells through their ability to modulate the
tumor microenvironment [16] and to promote the growth of
cancer cells [10,13,14,15,47]. However, there also exists substan-
tial evidence that fibroblasts from disease-free tissues have potent
tumor suppressive properties [48]. The characteristics of these
fibroblasts that contribute to either a tumor promoting or tumor
suppressive phenotype remain to be reconciled. In this study, we
identified both fibroblast mediated PGE2 secretion and autocrine
PGE2 signaling as a novel tumor promoting characteristic of these
cells. Moreover, we identify a novel tumor promoting mechanism
of these cells that is enhanced upon exposure to PGE2: the ability
to secrete factors (such as IL-6) that are essential for the expansion
of CD44
+/CD24
2/EpCAM
+ breast cancer cells.
There exist a number of citations to substantiate the notion that
fibroblasts harvested from resected breast tumor specimens are
aSMA+ and promote tumor growth in vivo (reviewed by [11,12].
These cells, commonly referred to as cancer associated fibroblasts
(CAFs), lack specific markers to discriminate them from fibroblasts
isolated from disease free tissues, because these normal fibroblast
counterparts acquire the expression of aSMA when grown in vitro.
Despite this, aSMA has become a widely used marker to
discriminate these cells. We harvested both types of fibroblasts:
Figure 2. Fibroblast mediated tumor promotion in vivo correlates with PGE2 secretion in vitro. (A) Resected tumors from mice inoculated
with a co-mix of tissue-derived fibroblasts from 5 different patients (A, C, E, I, K) and MCF7 breast cancer cells, or MCF7 cells injected alone (none).
Scale bar, 3 mm. Bottom left, tumor weights from mice inoculated with a co-mix of tissue-derived fibroblasts from 5 different patients (A, C, E, I, K)
and MCF7 breast cancer cells, or MCF7 cells injected alone (none). Statistics were performed using a single factor ANOVA, p=0.045). Bottom right,
average tumor volume (mm
3) from mice inoculated with a co-mix of tissue-derived fibroblasts from 5 different patients (A, C, E, I, K) and MCF7 breast
cancer cells, or MCF7 cells injected alone (none), assessed over 16 weeks. Statistics were performed using a Kruskal-Wallis nonparametric ANOVA
(p=0.02) followed by a two-tailed t test of means, comparing the volume of tumors derived from MCF7s co-mixed with patient sample K to those
derived from MCF7s co-mixed with patient sample I (p=0.004). Error bars, SEM. (B) Tumor incidence from mice inoculated with a co-mix of tissue-
derived fibroblasts from 5 different patients (A, C, E, I, K) and MCF7 breast cancer cells, or MCF7 cells injected alone (none). (C) Cox-2 and Cox-1
western blots of lysates prepared from various tissue-derived fibroblasts. Human mammary epithelial cells (HMECs) are shown as a positive control for
Cox-2. (D) PGE2- based immunoassay of CM from various tissue-derived fibroblasts. PGE2 concentrations are determined by a set of control standards
of known concentration, according to the manufacturer’s instructions. Statistics were performed using a single factor ANOVA (p=2.84610
212). Error
bars, SEM.
doi:10.1371/journal.pone.0024605.g002
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disease free reduction mammoplasty tissues. Both sources of
fibroblasts expressed the fibroblast markers vimentin, prolyl-4-
hydroxylase, and aSMA to unifying degrees in vitro, and both were
largely negative for breast epithelium specific cytokeratins CK18
and CK14.
Despite similar fibroblast marker expression in vitro, both sources
of fibroblasts had differences in their tumor promoting abilities in
vivo. Because tumor-promoting ability of our fibroblast populations
did not associate with any differences in marker expression
examined, nor did it associate with tissue source, we sought for
other characteristics of fibroblasts that may influence fibroblast
tumor promoting abilities. Because fibroblasts isolated from
dysplastic mouse skin support squamous cell carcinoma growth
in vivo through pro-inflammatory cytokine secretion [15], we
suspected that inflammatory mediators differ among the various
patient derived fibroblasts, which ultimately influence their
varying degrees of tumor promotion. Indeed, we found an
association between tumor promoting ability in vivo and high
PGE2 secretion in vitro. In addition, the ability to secrete PGE2
associates with the ability to expand CD44
+/CD24
2/EpCAM
+
breast cancer cells.
Interestingly, PGE2 alone was not sufficient to confer the
expansion of these cells, despite MCF7 expression of the
prostanoid receptors. PGE2 enhanced the inherent tumor
promoting abilities of fibroblasts as shown by in vitro tumorsphere
assays, and in vivo MCF7 limiting dilution experiments. Our data
suggest that this is largely due to the increased secretion of IL-6 in
response to PGE2, consistent with previous reports [49]. The
secretion of IL-6 by fibroblasts was necessary for expansion of
CD44
+/CD24
2/EpCAM
+ cells. Because this particular cell
population has been shown to contribute to tumorsphere
formation and seed tumor growth at limiting dilution [43,50],
we suspect that PGE2- mediated IL-6 secretion by fibroblasts was
largely responsible for the increased MCF7 tumorsphere forma-
tion and tumor formation observed upon exposure to fibroblast
CM.
Despite the requirement for IL-6 in mediating the tumor
promoting abilities of fibroblasts, we found that IL-6 alone was not
sufficient for expansion of CD44
+/CD24
2/EpCAM
+ cells in the
MCF7 cell line. This is in contrast to previous reports using
different breast cancer cell lines [46,51]. IL-6 has been implicated
in a positive feedback loop that perpetuates cellular transformation
through NFkB [46], which may drive the secretion of the other
necessary cytokines (in addition to IL-6) that are required for the
induction and maintenance of this aggressive cell state. We failed
to see activation of NFkB in response to CM from various tissue-
derived fibroblasts (data not shown), suggesting that this feedback
mechanism may not be activated in these cells, or only activated in
various subpopulations (i.e. CD44
+/CD24
2/EpCAM
+ cells).
The basal level of IL-6 varied widely among patient derived
breast fibroblasts, and also increased with passage number,
consistent with previous reports using primary fibroblasts [52].
However, neither the basal secretion of IL-6 nor the induced
secretion of IL-6 by PGE2 in fibroblasts correlated with fibroblast
tumor promoting ability in vivo or their ability to expand CD44
+/
CD24
2/EpCAM
+ cells in vitro. This is consistent with the notion
that IL-6 is required, but is not sufficient for expansion of CD44
+/
CD24
2/EpCAM
+ cells, nor is it sufficient for tumorsphere
formation. In addition, although IGF-II was significantly induced
by fibroblasts exposed to PGE2 more so than IL-6, we failed to
observe a requirement for this cytokine in expansion of CD44
+/
CD24
2/EpCAM
+ cells (data not shown). In lieu of these data, we
speculate that a certain stoichiometric balance of specific cytokines
is required to promote the expansion of these cells. This
stoichiometric balance may be obtained in vivo by secreted factors
from tumor cells as well as inflammatory cells in the tumor
microenvironment. It therefore follows that non-tumor promoting
fibroblasts (i.e., those with very low PGE2 secretion; i.e. tissue
sample I) perhaps lack the ability to activate certain pathways
downstream of PGE2 that modulate the balance of cytokine
secretion required for CD44
+/CD24
2/EpCAM
+ cell expansion
and tumor promoting ability in vivo. Further studies are needed to
determine what precise signaling pathways are activated in stromal
fibroblasts that activate Cox-2 expression and increase PGE2 and
IL-6 secretion. Interestingly, recent studies have shown that PTEN
loss in stromal fibroblasts significantly enhances fibroblast tumor
promoting ability through upregulation of genes associated with
ECM remodeling, wound healing and inflammatory responses
[53]. Further investigation into the activation of the PI3K/Akt,
Ras, and JNK pathways in stromal fibroblasts will elucidate which,
if any, of these molecular players are upstream of PGE2 and IL-6
secretion in these cells.
Since PGE2 enhanced fibroblast secretion of IL-6, it is plausible
that PGE2 also induces secretion of other cytokines yet to be
identified that together in concert with IL-6 orchestrate the
process of CD44
+/CD24
2/EpCAM
+ cell expansion. For exam-
ple, SDF1a is a growth factor secreted by myofibroblasts [10] that
promotes breast cancer cell growth [54] as well as expansion of
CD44
+/CD24
2 cells [55], and may be upregulated by PGE2 [56].
Also, IL-8 increases tumorsphere forming ability and the
percentage of ALDEFLUOR-positive breast cancer cells, which
enriches for cancer stem-like cell populations [57]. Further studies
are needed to elucidate if these cytokines contribute to IL-6
mediated expansion of CD44
+/CD24
2/EpCAM
+ cells.
In summary, our results indicate that the pro-inflammatory,
tumor-promoting phenotype of fibroblasts correlates with the
ability to secrete PGE2 and respond to PGE2 signaling. We were
unable to identify differential expression of well-established
markers of CAFs and tumor-promoting fibroblasts that correlated
Figure 3. PGE2 enhances the tumor promoting properties of breast tissue-derived fibroblasts. (A) CM from various patient derived
fibroblasts (E, F, J, K) were used to culture MCF7s for 6 days. The average percentage of CD44
+/CD24
2/EpCAM
+ cells was then assayed by FACS.
Statistics were performed using a single factor ANOVA (p=0.007) followed by a Student’s two-tailed t test of means: E vs. K, p=0.007; F vs. K,
p=0.005; J vs. K, p=0.01. Error bars, SEM. (B) MCF7 cells were cultured in either PRF-DMEM+10% CD-FBS supplemented with 1 nM E2 (positive
control), 0.5 mM PGE2, or vehicle for 6 days. The average percentage of CD44
+/CD24
2/EpCAM
+ cells was assayed by FACS. Data is plotted as average
of 3 independent experiments. Statistics were performed using a Student’s two tailed t test of means: EtOH vs. PGE2, p=0.001. Error bars, SEM. (C)
Quantification of MCF7 tumorspheres formed in the presence of CM from PGE2- or EtOH- fibroblasts from patient samples A, C, K, and I.
Quantification was performed using a Beckman Coulter Multisizer and plotted as a fold induction over vehicle. Statistics were performed using a
single factor ANOVA (p=3.25610
25) followed by a Student’s two-tailed t test of means comparing EtOH vs PGE2 for each patient sample: A,
p=0.014; C, p=0.001; K, p=0.0006; I, not significant). Error bars, SEM. (D), Tumor growth curves of 10
4 MCF7 cells primed in vitro with CM from PGE2-
treated fibroblasts from patient sample A (A-PGE2 CM) or CM from PGE2-treated fibroblasts from patient sample I (I-PGE2 CM). Statistics were
generated using a Student’s two-tailed t-test of means; p=0.03. Error bars, SEM (E) Top, H&E stains and immunohistochemical analysis (E-cadherin,
ER, CK8/18, p53) of tumors (2006). Scale bar, 50 mm. Bottom, quantification of the percentage of p53 positive cells within a given field based on the
tumor sections from (D) Statistics were performed using a Student’s two-tailed t-test of means, p=0.02).
doi:10.1371/journal.pone.0024605.g003
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PLoS ONE | www.plosone.org 10 September 2011 | Volume 6 | Issue 9 | e24605Figure 4. Tissue-derived fibroblasts secrete IL-6, which is necessary, but not sufficient, for the expansion of CD44
+/CD24
2/ESA
+
cells. (A) Immunoblot for IL-6 expression in CM from tissue derived fibroblasts (from patient samples C, A, G) exposed to either EtOH (vehicle) or
0.5 mM PGE2. (B) CM from various tissue derived fibroblasts treated with either 0.5 mM PGE2 or EtOH (vehicle) were assayed for the levels of IL-6
secretion using a human IL-6 ELISA. Concentration is normalized to the cell number post treatment and plotted as the geometric mean of the fold
induction (in arbitrary units). Error bars, SEM. (C) Quantification of the average percentage of CD44
+/CD24
2/EpCAM
+ MCF7 cells after 6 day exposure
to CM from PGE2 or EtOH treated fibroblasts from patient sample A (A-CM), or CM from PGE2 or EtOH treated fibroblasts from patient sample I (I-CM)
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failed to identify a correlation between fibroblasts isolated from
invasive carcinomas (either ER+ or ER2) and a high PGE2
secreting, tumor promoting phenotype, as compared to those
isolated from reduction mammoplasty tissues. Our results suggest
that tumor promoting fibroblasts secrete PGE2 and mediate
autocrine PGE2 signaling, thereby activating the increased
secretion of IL-6, which is required for expansion of breast cancer
stem-like cells. In fact, our results suggest that the tumor
promoting ability of fibroblasts associates moreso with PGE2
secretion and signaling than if these fibroblasts are derived from
diseased tissues. The identification of specific markers for these
tumor promoting fibroblasts would likely allow for the observation
of more robust phenotypic discrepancies between various
fibroblast tissue sources, and would possibly discriminate among
patients that would likely benefit from tumor-associated stroma
drug targeting strategies for use as adjuvant therapies in the
treatment of human breast cancers.
Supporting Information
Figure S1 Characterization of patient derived fibro-
blasts from human breast tumor tissues and reduction
mammoplasty tissues. (A) Immunofluorescence results for the
expression of mesenchymal markers vimentin and prolyl-4-
hydroxylase (P4H), and myofibroblast/cancer associated fibroblast
markers aSMA and Caveolin-1, in tissue-derived fibroblasts from
patient samples A, C, E, I, M, N, and K. Nuclei are stained with
DAPI. Scale bar, 50 mm. (B) Immunofluorescence results for the
expression of the breast epithelial marker CK18 in tissue-derived
fibroblasts from patient sample C, which showed high transcript
levels of CK18 in Fig. 1A. MCF7 cells are a positive control.
(TIF)
Figure S2 Tissue-derived fibroblasts express Cox-2
transcript and the prostanoid receptors. (A) Quantitative
RT-PCR for the relative levels of Cox-2 transcript in tissue derived
fibroblasts from patient samples A, N, I, and F. MCF7 and
SUM1315 breast cancer cells serve as negative and positive
controls for Cox-2 expression, respectively. (B) Western blot for
EP1, EP2, EP3 and EP4 expression in lysates extracted from
tissue-derived fibroblasts (patients A and I), MCF7 and HCC1428
breast cancer cell lines.
(TIF)
Figure S3 PGE2 enhances the ability of fibroblasts to
expand CD44
+/CD24
2/ESA
+ cells. FACS dot plots of MCF7
cells treated with CM from tissue derived fibroblasts (patient
samples I and A) treated with EtOH (vehicle) or 0.5 mM PGE2.
Cell populations are gated first for EpCAM
+, then for CD44
+ and
CD24
2.
(TIF)
Figure S4 Basal levels of IL-6 in various patient derived
fibroblasts. (A) Cytokine array results of CM from PGE2 and
EtOH (vehicle) treated fibroblasts (from patient sample A). Data is
plotted as a normalized fold induction over vehicle. (B)
Quantification of the average basal levels of IL-6 secretion by
various patient-derived fibroblasts using a human IL-6 ELISA. IL-
6 secretion was normalized to the total number of fibroblasts
present at the time of CM harvest.
(TIF)
Table S1 Primer sequences used for quantitative RT-
PCR.
(PDF)
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